This Review examines the current evidence supporting a role for intracellular amyloid-β (Aβ) in the pathogenesis of Alzheimer's disease. Intracellular Aβ accumulation appears to be an early event in the disease, and may be a source for extracellular deposits as the disease progresses.
Aβ can be produced within cells or taken up from extracellular sources through receptor binding and subsequent internalization. This leads to accumulation within endosomes, multivesicular bodies, lysosomes, mitochondria, the endoplasmic reticulum and trans-Golgi network, and the cytosol.
Oligomeric Aβ assembly states have been implicated as the critical pathological species. Aβ oligomerization may commence within cells, possibly through membrane interactions, and these Aβ oligomers may act intracellularly to cause neuronal dysfunction, or pass into the extracellular space.
Intracellular Aβ in transgenic mouse models of Alzheimer's disease is associated with cognitive deficits, tau phosphorylation, neuronal loss and synaptic dysfunction.
Various treatments and paradigms affect intracellular Aβ, including aging, docosahexaenoic acid, insulin, learning, stress and the Alzheimer's disease risk factor allele APOE*ε4.
The primal role that the amyloid-β (Aβ) peptide has in the development of Alzheimer's disease is now almost universally accepted. It is also well recognized that Aβ exists in multiple assembly states, which have different physiological or pathophysiological effects. Although the classical view is that Aβ is deposited extracellularly, emerging evidence from transgenic mice and human patients indicates that this peptide can also accumulate intraneuronally, which may contribute to disease progression.
Subscribe to Journal
Get full journal access for 1 year
only $22.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizine 64, 146–148 (1907).
Glenner, G. G. & Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890 (1984).
Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245–4249 (1985).
Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E. & Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl Acad. Sci. USA 85, 4051–4055 (1988).
Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913–4917 (1986).
Ihara, Y., Nukina, N., Miura, R. & Ogawara, M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. (Tokyo) 99, 1807–1810 (1986).
Kosik, K. S., Joachim, C. L. & Selkoe, D. J. Microtubule-associated protein tau (τ) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044–4048 (1986).
Rozemuller, J. M., Eikelenboom, P. & Stam, F. C. Role of microglia in plaque formation in senile dementia of the Alzheimer type. An immunohistochemical study. Virchows Arch. B Cell Pathol. 51, 247–254 (1986).
Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nature Med. 12, 1005–1015 (2006).
Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134–147 (1997).
McGeer, P. L., Rogers, J. & McGeer, E. G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis. 9, 271–276 (2006).
Allinson, T. M., Parkin, E. T., Turner, A. J. & Hooper, N. M. ADAMs family members as amyloid precursor protein α-secretases. J. Neurosci. Res. 74, 342–352 (2003).
Vassar, R. et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).
Hussain, I. et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14, 419–427 (1999).
Sinha, S. et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402, 537–540 (1999).
Wolfe, M. S. et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513–517 (1999).
Steiner, H. et al. PEN-2 is an integral component of the γ-secretase complex required for coordinated expression of presenilin and nicastrin. J. Biol. Chem. 277, 39062–39065 (2002).
Francis, R. et al. aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev. Cell 3, 85–97 (2002).
Levitan, D. et al. PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling. Proc. Natl Acad. Sci. USA 98, 12186–12190 (2001).
Yu, G. et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature 407, 48–54 (2000).
Kojro, E. & Fahrenholz, F. The non-amyloidogenic pathway: structure and function of α-secretases. Subcell. Biochem. 38, 105–127 (2005).
Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B. & Selkoe, D. J. β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. 268, 3021–3024 (1993).
Jarrett, J. T., Berger, E. P. & Lansbury, P. T. Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693–4697 (1993).
Younkin, S. G. The role of Aβ 42 in Alzheimer's disease. J. Physiol. Paris 92, 289–292 (1998).
St George-Hyslop, P. H. & Petit, A. Molecular biology and genetics of Alzheimer's disease. C. R. Biol. 328, 119–130 (2005).
Haass, C. et al. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway. Nature Med. 1, 1291–1296 (1995).
Nilsberth, C. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nature Neurosci. 4, 887–893 (2001).
Guo, Q. et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature Med. 5, 101–106 (1999).
Jankowsky, J. L. et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum. Mol. Genet. 13, 159–170 (2004).
Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature Genet. 38, 24–26 (2006).
Cabrejo, L. et al. Phenotype associated with APP duplication in five families. Brain 129, 2966–2976 (2006).
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E. & Troncoso, J. C. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125, 489–492 (2001).
Mori, C. et al. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid 9, 88–102 (2002).
Grundke-Iqbal, I. et al. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc. Natl Acad. Sci. USA 86, 2853–2857 (1989).
Blurton-Jones, M. & Laferla, F. M. Pathways by which Aβ facilitates tau pathology. Curr. Alzheimer Res. 3, 437–448 (2006).
Gouras, G. K. et al. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 156, 15–20 (2000).
Takahashi, R. H. et al. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 869–1879 (2002). Using electron microscope analysis, this paper shows that in AD brains, intraneuronal Aβ accumulates within the multivesicular bodies.
D'Andrea, M. R. et al. The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci. Lett. 342, 114–118 (2003).
Ohyagi, Y. et al. Intraneuronal amyloid β42 enhanced by heating but counteracted by formic acid. J. Neurosci. Methods 159, 134–138 (2007).
Chui, D. H. et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nature Med. 5, 560–564 (1999).
Knobloch, M., Konietzko, U., Krebs, D. C. & Nitsch, R. M. Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice. Neurobiol. Aging, 31 July 2006 (doi:10.1016/j.neurobiolaging.2006.06.019). Provides evidence linking intraneuronal Aβ accumulation to cognitive deficits in transgenic mice.
Kuo, Y. M. et al. The evolution of Aβ peptide burden in the APP23 transgenic mice: implications for Aβ deposition in Alzheimer disease. Mol. Med. 7, 609–618 (2001).
Li, Q. X. et al. Intracellular accumulation of detergent-soluble amyloidogenic Aβ fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J. Neurochem. 72, 2479–2487 (1999).
Lord, A. et al. The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging 27, 67–77 (2006).
Oakley, H. et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140 (2006).
Oddo, S. et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39, 409–421 (2003). Provides the earliest in vivo evidence that links intraneuronal Aβ to synaptic dysfunction, showing that intraneuronal Aβ accumulation leads to a profound LTP deficit in 3xTg-AD mice.
Wirths, O. et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306, 116–120 (2001).
Oddo, S., Caccamo, A., Smith, I. F., Green, K. N. & LaFerla, F. M. A dynamic relationship between intracellular and extracellular pools of Aβ. Am. J. Pathol. 168, 184–194 (2006).
Wegiel, J. et al. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol. (Berl) 113, 389–402 (2007).
Kinoshita, A. et al. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J. Cell Sci. 116, 3339–3346 (2003).
Breen, K. C., Bruce, M. & Anderton, B. H. β amyloid precursor protein mediates neuronal cell–cell and cell–surface adhesion. J. Neurosci. Res. 28, 90–100 (1991).
Sabo, S. L., Ikin, A. F., Buxbaum, J. D. & Greengard, P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J. Cell Biol. 153, 1403–1414 (2001).
Xu, H., Greengard, P. & Gandy, S. Regulated formation of Golgi secretory vesicles containing Alzheimer β-amyloid precursor protein. J. Biol. Chem. 270, 23243–23245 (1995).
Mizuguchi, M., Ikeda, K. & Kim, S. U. Differential distribution of cellular forms of β-amyloid precursor protein in murine glial cell cultures. Brain Res. 584, 219–225 (1992).
Wertkin, A. M. et al. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular β-amyloid or A4 peptides. Proc. Natl Acad. Sci. USA 90, 9513–9517 (1993).
Martin, B. L. et al. Intracellular accumulation of β-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J. Biol. Chem. 270, 26727–26730 (1995).
Rogaeva, E. et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genet. 39, 168–177 (2007).
Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J. & Younkin, S. G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728–730 (1992).
Koo, E. H. & Squazzo, S. L. Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386–17389 (1994).
Perez, R. G. et al. Mutagenesis identifies new signals for β-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Aβ42. J. Biol. Chem. 274, 18851–18856 (1999).
Cam, J. A. et al. The low density lipoprotein receptor-related protein 1B retains β-amyloid precursor protein at the cell surface and reduces amyloid-β peptide production. J. Biol. Chem. 279, 29639–29646 (2004).
Busciglio, J., Gabuzda, D. H., Matsudaira, P. & Yankner, B. A. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl Acad. Sci. USA 90, 2092–2096 (1993). Provides strong evidence that Aβ in neurons is generated by the secretory pathway.
Cook, D. G. et al. Alzheimer's A β(1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nature Med. 3, 1021–1023 (1997).
Lee, S. J. et al. A detergent-insoluble membrane compartment contains A β in vivo. Nature Med. 4, 730–734 (1998).
Skovronsky, D. M., Doms, R. W. & Lee, V. M. Detection of a novel intraneuronal pool of insoluble amyloid β protein that accumulates with time in culture. J. Cell Biol. 141, 1031–1039 (1998).
Wild-Bode, C. et al. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J. Biol. Chem. 272, 16085–16088 (1997).
Hartmann, T. et al. Distinct sites of intracellular production for Alzheimer's disease A β40/42 amyloid peptides. Nature Med. 3, 1016–10120 (1997). Shows that both Aβ 40 and Aβ 42 are generated intracellularly but at different sites.
Bu, G., Cam, J. & Zerbinatti, C. LRP in amyloid-β production and metabolism. Ann. N. Y. Acad. Sci. 1086, 35–53 (2006).
Deane, R. et al. RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. Nature Med. 9, 907–913 (2003).
Nagele, R. G., D'Andrea, M. R., Anderson, W. J. & Wang, H. Y. Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110, 199–211 (2002). Shows that Aβ binds to α7nAChR and suggests that it is subsequently internalized, thus providing a mechanism for intraneuronal Aβ accumulation.
Yazawa, H. et al. β amyloid peptide (Aβ42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 15, 2454–2462 (2001).
Clifford, P. M. et al. Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons. Brain Res. 1142, 223–236 (2007).
Wang, H. Y. et al. β-Amyloid1–42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 275, 5626–5632 (2000).
Oddo, S. et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 102, 3046–3051 (2005).
Zerbinatti, C. V. et al. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Aβ42 accumulation in amyloid model mice. J. Biol. Chem. 281, 36180–36186 (2006).
Yan, S. D. et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685–691 (1996).
Sasaki, N. et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888, 256–262 (2001).
Du Yan, S. et al. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 5296–5301 (1997).
Iribarren, P., Zhou, Y., Hu, J., Le, Y. & Wang, J. M. Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. Immunol. Res. 31, 165–176 (2005).
Snyder, E. M. et al. Regulation of NMDA receptor trafficking by amyloid-β. Nature Neurosci. 8, 1051–1058 (2005).
Bi, X., Gall, C. M., Zhou, J. & Lynch, G. Uptake and pathogenic effects of amyloid β peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112, 827–840 (2002).
Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333–1341 (2003).
Minkeviciene, R., Banerjee, P. & Tanila, H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 311, 677–682 (2004).
Cleary, J. P. et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nature Neurosci. 8, 79–84 (2005).
Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).
Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B. & Selkoe, D. J. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831–10839 (2000). Using cells from the human brain, this paper shows that Aβ oligomerization starts intraneuronally.
Oddo, S. et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem. 281, 1599–1604 (2006).
Takahashi, R. H. et al. Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592–3599 (2004). Shows that Aβ oligomers accumulate intraneuronally in AD brain.
Kim, S. I., Yi, J. S. & Ko, Y. G. Amyloid β oligomerization is induced by brain lipid rafts. J. Cell Biochem. 99, 878–889 (2006).
Kawarabayashi, T. et al. Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 24, 3801–3809 (2004).
Waschuk, S. A., Elton, E. A., Darabie, A. A., Fraser, P. E. & McLaurin, J. A. Cellular membrane composition defines Aβ-lipid interactions. J. Biol. Chem. 276, 33561–33568 (2001).
Matsuzaki, K. et al. Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes. Biochim. Biophys. Acta 1768, 122–130 (2007).
Wakabayashi, M., Okada, T., Kozutsumi, Y. & Matsuzaki, K. GM1 ganglioside-mediated accumulation of amyloid β-protein on cell membranes. Biochem. Biophys. Res. Commun. 328, 1019–1023 (2005).
Yamamoto, N. et al. Accelerated Aβ aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569, 135–139 (2004).
D'Andrea, M. R., Nagele, R. G., Wang, H. Y., Peterson, P. A. & Lee, D. H. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120–134 (2001). Provides evidence suggesting that in the brains of patients with AD, intracellular Aβ accumulation may lead to neuronal death, and that after being released in the extracellular compartment, it can contribute to the formation of plaques.
Bahr, B. A. et al. Amyloid β protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J. Comp. Neurol. 397, 139–147 (1998).
Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321–332 (2004). Shows that Aβ immunotherapy clears intraneuronal Aβ accumulation, which leads to the removal of tau deposits, thus linking intracellular Aβ and tau pathology.
Gouras, G. K., Almeida, C. G. & Takahashi, R. H. Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 26, 1235–1244 (2005).
Tseng, B. P., Kitazawa, M. & LaFerla, F. M. Amyloid β-peptide: the inside story. Curr. Alzheimer Res. 1, 231–239 (2004).
Langui, D. et al. Subcellular topography of neuronal Aβ peptide in APPxPS1 transgenic mice. Am. J. Pathol. 165, 1465–1477 (2004).
Almeida, C. G., Takahashi, R. H. & Gouras, G. K. β-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin–proteasome system. J. Neurosci. 26, 4277–4288 (2006).
Gregori, L., Fuchs, C., Figueiredo-Pereira, M. E., Van Nostrand, W. E. & Goldgaber, D. Amyloid β-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270, 19702–19708 (1995).
Oh, S. et al. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech. Ageing Dev. 126, 1292–1299 (2005).
Tseng, B. P., Green, K. N., Chan, J., Blurton-Jones, M. & LaFerla, F. Aβ inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging (in the press).
Manczak, M. et al. Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15, 1437–1449 (2006).
Hansson, C. A. et al. Nicastrin, presenilin, APH-1, and PEN-2 form active γ-secretase complexes in mitochondria. J. Biol. Chem. 279, 51654–51660 (2004).
Caspersen, C. et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 19, 2040–2041 (2005).
Keil, U. et al. Mitochondrial dysfunction induced by disease relevant AβPP and tau protein mutations. J. Alzheimers Dis. 9, 139–146 (2006).
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L. & LaFerla, F. M. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675–688 (2005). Shows that intraneuronal Aβ accumulation is responsible for the onset of cognitive decline in the 3xTg-AD.
Morris, R. G., Anderson, E., Lynch, G. S. & Baudry, M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319, 774–776 (1986).
Gong, B. et al. Ubiquitin hydrolase Uch-L1 rescues β-amyloid-induced decreases in synaptic function and contextual memory. Cell 126, 775–788 (2006).
Green, K. N. et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 27, 4385–4395 (2007).
Hashimoto, M. et al. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid β-infused rats. J. Nutr. 135, 549–555 (2005).
Lim, G. P. et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 3032–3040 (2005).
Gasparini, L. et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 2561–2570 (2001).
Billings, L. M., Green, K. N., McGaugh, J. L. & LaFerla, F. M. Learning decreases Aβ*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci. 27, 751–761 (2007).
Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L. & LaFerla, F. M. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 26, 9047–9056 (2006).
Sparks, D. L. et al. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88–94 (1994).
Misonou, H., Morishima-Kawashima, M. & Ihara, Y. Oxidative stress induces intracellular accumulation of amyloid β-protein (Aβ) in human neuroblastoma cells. Biochemistry 39, 6951–6959 (2000).
Hasegawa, T. et al. Homocysteic acid induces intraneuronal accumulation of neurotoxic Aβ42: implications for the pathogenesis of Alzheimer's disease. J. Neurosci. Res. 80, 869–876 (2005).
D'Andrea, M. R., Nagele, R. G., Wang, H. Y. & Lee, D. H. Consistent immunohistochemical detection of intracellular β-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. Neurosci. Lett. 333, 163–166 (2002).
D'Andrea, M. R. et al. Lipofuscin and Aβ42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci. Lett. 323, 45–49 (2002).
LaFerla, F. M., Troncoso, J. C., Strickland, D. K., Kawas, C. H. & Jay, G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Aβ stabilization. J. Clin. Invest. 100, 310–320 (1997).
Mochizuki, A., Tamaoka, A., Shimohata, A., Komatsuzaki, Y. & Shoji, S. Aβ42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet 355, 42–43 (2000).
Mendell, J. R., Sahenk, Z., Gales, T. & Paul, L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch. Neurol. 48, 1229–1234 (1991).
Sarkozi, E., Askanas, V., Johnson, S. A., Engel, W. K. & Alvarez, R. B. β-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 4, 815–818 (1993).
Askanas, V., Engel, W. K. & Alvarez, R. B. Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 43, 1265–1267 (1993).
Kimura, N. et al. Age-related changes of intracellular Aβ in cynomolgus monkey brains. Neuropathol. Appl. Neurobiol. 31, 170–180 (2005).
Martin, L. J., Pardo, C. A., Cork, L. C. & Price, D. L. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am. J. Pathol. 145, 1358–1381 (1994).
Cummings, B. J., Su, J. H., Cotman, C. W., White, R. & Russell, M. J. β-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol. Aging 14, 547–560 (1993).
Torp, R. et al. Ultrastructural evidence of fibrillar β-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. Neuroscience 96, 495–506 (2000).
Cruz, J. C. et al. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo. J. Neurosci. 26, 10536–10541 (2006).
Casas, C. et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289–1300 (2004). Provides in vivo evidence that intraneuronal Aβ accumulation is toxic and leads to cell death.
Van Broeck, B. et al. Intraneuronal amyloid β and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiol. Aging 16 Nov 2006 (doi:10.1016/j.neurobiolaging.2006.10.016).
Shie, F. S., LeBoeuf, R. C. & Jin, L. W. Early intraneuronal Aβ deposition in the hippocampus of APP transgenic mice. Neuroreport 14, 123–129 (2003).
Magrane, J. et al. Intraneuronal β-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J. Neurosci. 25, 10960–10969 (2005).
Suo, Z. et al. GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiol. Aging 2 October 2006 (doi: 10.1016/j.neurobiolaging.2006.08.013).
Sugarman, M. C. et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle. Proc. Natl Acad. Sci. USA 99, 6334–6339 (2002).
Kitazawa, M., Green, K. N., Caccamo, A. & LaFerla, F. M. Genetically augmenting Aβ42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am. J. Pathol. 168, 1986–1997 (2006).
Moussa, C. E. et al. Transgenic expression of β-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J. 20, 2165–2167 (2006).
Echeverria, V. et al. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the β-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 129, 583–592 (2004).
Tawil, R. & Griggs, R. C. Inclusion body myositis. Curr. Opin. Rheumatol. 14, 653–657 (2002).
Askanas, V. & Engel, W. K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition. Neurology 66, S39–S48 (2006).
We thank M. Blurton-Jones and A. Parachikova for critically reading the manuscript and for assistance with the figures. This work was supported in part by grants from the Alzheimer's Association and the National Institutes of Health.
The authors declare no competing financial interests.
- Declarative memory
Aspect of human memory that stores facts and experiences. It can be further subdivided into episodic memory and semantic memory.
A lesion or sign, the occurrence of which provides evidence that a particular disease is present.
- Multivesicular body
(MVB). MVBs have a role in transporting cargo to the lysosome system for degradation, and throughout the neuron for signalling purposes, and are important in regulating and degrading transmembrane proteins.
Antibody recognition site of a terminal sequence in which the same sequence of amino acids are not recognized when located internally as part of the intact protein.
- Mild cognitive impairment
(MCI). A transition stage between the cognitive changes of normal aging and Alzheimer's disease.
- Retromer recycling endosomes
The retromer complex has been shown to be important in recycling transmembrane receptors from endosomes to the trans-Golgi network.
The full-length, native polypeptide, before proteolytic cleavage events that might occur during maturation.
A fragment of a genomic sequence that includes the exons and introns and is cloned into a eukaryotic expression vector.
- Lipid raft
A specialized membrane domain that is enriched in cholesterol.
- Nucleation seed
A molecule that facilitates the assembly of a polymeric structure.
Isolated synapse of a neuron obtained via homogenization of nerve tissue.
- Ubiquitin–proteasome system
Proteasomes are large protein complexes that degrade damaged or superfluous proteins that are tagged by a small protein called ubiquitin.
About this article
Cite this article
LaFerla, F., Green, K. & Oddo, S. Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 8, 499–509 (2007). https://doi.org/10.1038/nrn2168
Analytical Chemistry (2020)
The Alzheimer Disease-Causing Presenilin-1 L435F Mutation Causes Increased Production of Soluble Aβ43 Species in Patient-Derived iPSC-Neurons, Closely Mimicking Matched Patient Brain Tissue
Journal of Neuropathology & Experimental Neurology (2020)
Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer’s disease
Alzheimer's Research & Therapy (2020)
Tanshinone IIA ameliorates cognitive deficits by inhibiting endoplasmic reticulum stress-induced apoptosis in APP/PS1 transgenic mice
Neurochemistry International (2020)